CL vs SYRE · P/E 34, rev $10.69B vs $7.60B cap
Colgate-Palmolive Company (CL) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported CL revenue for 2026-06-30 was $10.69B. Net income was $1.34B. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
CL currently screens at market cap $70.88B and trailing P/E 34.3. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the CL and SYRE stock pages for the full models.
Not investment advice.